[1] Liu Xiaoyuan?YU Xiaoyong,.Interpretation of Expert Consensus Guidelines for Clinical Application of Chinese Patent Medicine in Treatment of Diabetes Kidney Disease [J]. Modern Traditional Chinese Medicine, 2023, (01): 24-30. [doi: 10.13424/j.cnki.mtcm.2023.01.005]
Interpretation of Expert Consensus Guidelines for Clinical Application of Chinese Patent Medicine in Treatment of Diabetes Kidney Disease
- Article number:
- 1672-0571(2023)01-0024-07
- ZTFLH:
- R256.5??
- Code:
- A??
- Abstract:
- In 2022，the expert consensus on clinical application of Chinese patentmedicine for diabetes kidney disease will be officially released.Based on solving key clinical problems，the consensus recommended 16 kinds of Chinese patent medicines for the treatment of diabetes kidney disease，involving six types of TCM syndromes，and recommended the treatment mechanism，efficacy indicators，usage and dosage，precautions and applicable population of each kind of Chinese patent medicine.This paper mainly introduces the background and method of the consensus，and interprets the relevant contents of the expert consensus.
References:
［1］Strelitz J,Ahern AL,Long GH,et al.Changes in behaviors after diagnosis of type 2 diabetes and 10-year incidence of cardiovascular disease and mortality［J］.Cardiovasc Diabetol,2019,18(1)：98. ［2］［LI Y，TENG D，SHI X，et al．Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association： national cross sectional study［J］．BMJ，2020，369（1）：m997.
［3］TUTTLE K R，BAKRIS G L，BILOUS R W，et al．Diabetic kidney disease：a report from an ADA consensus conference［J］．American Journal of Kidney Diseases，2014，64（4）：510-533．
［4］ZHANG XX，KONG J，YUN K.Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China：a meta analysis of observational studies［J］.Journal of Diabetes Research， 2020，2020：2315607.
［5］YANG C，WANG H B，ZHAO X J，et al.CKD in China：evolving spectrum and public health implications［J］.American Journal of Kidney Diseases，2020，76(2)：258-264.
［6］Lu H,Deng S,Zheng M,et al.iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy［J］.Clin Proteomics,2019,16：33.
［7］郝玉婷,林洁,秦杰.联合检测标志物在糖尿病肾病早期肾损伤诊断中的临床价值［J］.西部医学,2018,30(10):1535-1538,1546.
［8］黄诗雄,邓德强,高旋.糖尿病肾病中医治疗研究进展［J］.新中医,2022,54（9):16-22.
［9］蒋宇彤,刘阳.基于“扶正祛邪”理论治疗糖尿病肾病方证探析［J/OL］.实用中医内科杂志：1-3［2022-10-15］.http://kns.cnki.net/kcms/detail/21.1187.R.20220919.
1000.004.html
［10］中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏 病防治指南(2021 年版)［J］.中华糖尿病杂志，2021，13(8)：762-784.
［11］ANDRASSY K M.Comments on “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease”［J］.Kidney International，2013，84(3)：622-623.
［12］高彦彬，刘铜华，李平.糖尿病肾病中医防治指南［J］.中国中医药现代远程教育，2011，9(4)：151-153.
［13］李吉萍,袁野,张文友.西洋参茎叶皂苷对糖尿病大鼠氧化损伤和血管内皮功能的影响［J］.中国药理学通报,2017,33(12):1698-1702.
［14］蔡月琴,陈方明,方明笋,等.土茯苓总黄酮抗单侧输尿管梗阻大鼠肾间质纤维化研究［J］.浙江中医药大学学报,2017,41(12):944-950.
［15］付兆鑫,刘中柱,郑奕楠.黄芪甲苷治疗肾脏疾病的研究进展［J］.上海医药,2022,43（5):43-45+57.
［16］赵瀚微,陈文阁.大黄素通过调节ILK/MAPK信号通路对糖尿病肾脏病大鼠肾组织的改善作用［J］.中医药导报,2022,28（8):6-11.
［17］张璇,姜睿斌,张晓菊,等.基于NF-κB通路研究生地黄-玄参对糖尿病肾病大鼠肾脏微炎症状态的影响［J］.国际中医中药杂志,2022,44（1):49-55.
［18］董奥,孔琪,谭小月,等.五味子乙素对缺氧/复氧肾小管上皮细胞凋亡与自噬的影响［J］.中华中医药杂志,2020,35(12):6046-6049.
［19］朱军,赵希敏.肉苁蓉总苷预处理对缺血再灌注肾损伤保护作用的实验研究［J］.同济大学学报(医学版),2015,36（2):37-40.
［20］方朝慧,胡惠萍.达格列净联合百令胶囊治疗糖尿病肾病的疗效及对其肾功能的影响［J］.糖尿病新世界，2022,25(16):17-20.
［21］汤礼萍,朱力,刘娜,等.金水宝胶囊联合厄贝沙坦治疗糖尿病肾病的疗效及安全性［J］.临床合理用药杂志,2022,15（7):73-75.
［22］张萌,杨立诚,陈娟,等.牡丹皮多糖组分对糖尿病肾病大鼠肾脏损伤的保护作用研究［J］.中国中药杂志,2022,47（3):713-720.
［23］张小荣.肾炎舒颗粒联合氯沙坦治疗早期糖尿病肾病的疗效及对肾功能炎性因子和血糖的影响［J］.临床合理用药杂志,2017,10(17):59-60.
［24］张晓丽,张金梅,武文斌,等.肾炎舒颗粒对早期糖尿病肾病患者尿足细胞及肾小管功能的影响［J］.山东医药,2016,56(33):75-77.
［25］王美子,王玉,万毅刚,等.黄蜀葵花总黄酮抑制糖尿病肾脏疾病大鼠肾组织周细胞-肌成纤维细胞转分化的作用和机制［J］.中华中医药杂志,2022,37（5):2856-2861.
［26］涂小刚,王芳,方文娟,等.复方肾炎片治疗肥胖体质糖尿病肾病的临床观察［J］.临床肾脏病杂志,2015,15（2):120-121.
［27］郭莉江,杨晓蓉,周淑红.复方丹参滴丸对糖尿病早期肾病大鼠的影响［J］.兰州大学学报(医学版),2022,48（7):10-15.
［28］陈建寿,刘志鹏,陈珊珊.通心络胶囊联合津力达颗粒对Ⅳ期糖尿病肾病患者尿蛋白、肾功能的影响［J］.世界中医药,2019,14(10):2670-2674.
［29］张丽,张然,田领,等.通心络胶囊联合胰岛素治疗早期糖尿病肾病的临床观察［J］.南昌大学学报(医学版),2016,56（1):74-76.
［30］孙守萍.尿毒清颗粒联合百令胶囊治疗早期糖尿病肾病临床观察［J］.光明中医,2021,36(13):2112-2115.
［31］罗璇,韦少恒,韦珍红.肾衰宁胶囊联合阿托伐他汀治疗糖尿病肾病的临床效果［J］.广西医学,2022,44(13):1462-1466.
［32］左建娇,王津,魏萱,等.雷公藤多苷片联合百令胶囊治疗Ⅳ期糖尿病肾病的临床效果［J］.解放军医药杂志,2022,34（6):131-134.
［33］许叶文,王亚娟,周国儿.消渴益肾方联合雷公藤多苷片治疗糖尿病肾病的效果观察［J］.中国中西医结合肾病杂志,2022,23（6):530-532.
Memo
基金项目：国家自然科学基金项目（82174366）